Optimist Retirement Group LLC Acquires New Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Optimist Retirement Group LLC bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the second quarter, Holdings Channel reports. The fund bought 1,391 shares of the biotechnology company’s stock, valued at approximately $220,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after buying an additional 243,180 shares in the last quarter. Capital International Investors grew its holdings in Sarepta Therapeutics by 1.6% during the 1st quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after buying an additional 76,032 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in Sarepta Therapeutics by 7.9% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after buying an additional 319,444 shares in the last quarter. Wellington Management Group LLP grew its holdings in Sarepta Therapeutics by 5.6% during the 4th quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock valued at $398,025,000 after buying an additional 217,810 shares in the last quarter. Finally, Farallon Capital Management LLC grew its holdings in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 0.5 %

Shares of SRPT opened at $125.01 on Thursday. The firm has a market cap of $11.82 billion, a P/E ratio of 1,136.45 and a beta of 0.81. The stock has a 50 day simple moving average of $138.75 and a two-hundred day simple moving average of $132.67. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, analysts forecast that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 52,801 shares of company stock worth $8,399,586. 7.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SRPT shares. Needham & Company LLC reaffirmed a “buy” rating and set a $235.00 target price on shares of Sarepta Therapeutics in a report on Thursday, June 27th. Cantor Fitzgerald cut their price objective on Sarepta Therapeutics from $167.00 to $152.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Bank of America boosted their price objective on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Sarepta Therapeutics in a report on Friday, September 6th. Finally, Barclays cut their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $187.39.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.